Clinical Trial Update: An Evaluation of Three Doses of NS 2330 in Patients With Mild to Moderate Dementia of the Alzheimer's Type [Phase 2]

View source ↗

Summary

This update reports results from a Phase 2 trial evaluating three doses of NS 2330 in patients with mild to moderate Alzheimer's disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• NS 2330 (NS-2330)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Alzheimer Disease | Phase 2 | Status: COMPLETED